Payment overview · 2025
General Payments
$472.15
22 reported records · 9 companies
Healthcare provider profile · identity verified
Luis Glodowski, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Cardiovascular Disease · SUNNYSIDE, NY · NPI 1477508158
Verified facts
What the public records show
CMS Open Payments records show Luis Glodowski, MD received $472.15 in general payments during 2025 across 22 reported records.
AstraZeneca Pharmaceuticals LP accounted for 56.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Entresto, Farxiga, Jardiance, Lokelma, Trelegy Ellipta.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BEVESPI AEROSPHERE as an associated drug or biological on 763 records involving 473 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Bevespi Aerosphere by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 94 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Lokelma by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 114 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 129 claims for Trelegy Ellipta by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Entresto by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $266.53 | 56.5% | 12 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $44.72 | 9.5% | 2 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $32.79 | 6.9% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $31.57 | 6.7% | 2 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $23.49 | 5.0% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $22.36 | 4.7% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $19.76 | 4.2% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $17.62 | 3.7% | 1 | 2025 |
| Medicure Pharma Inc. | Unresolved — no canonical attribution shown | $13.31 | 2.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $472.15 | 22 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $86.41 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $83.56 | 5 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $46.93 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $44.72 | 2 | 2025 |
Source payment records
|
|||||
| AMVUTTRA Normalized: amvuttra |
Drug | Alnylam Pharmaceuticals Inc. | $32.79 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $31.57 | 2 | 2025 |
Source payment records
|
|||||
| LOKELMA Normalized: lokelma |
Drug | AstraZeneca Pharmaceuticals LP | $24.68 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $23.49 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $22.36 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $19.76 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $19.76 | 1 | 2025 |
Source payment records
|
|||||
| Repatha Normalized: repatha |
Biological | Amgen Inc. | $17.62 | 1 | 2025 |
Source payment records
|
|||||
| Zypitamag Normalized: zypitamag |
Drug | Medicure Pharma Inc. | $13.31 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ENTRESTO entresto |
2025 | Entresto | 2024 | 49 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 94 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 114 | exact normalized | Medicare Part D |
| LOKELMA lokelma |
2025 | Lokelma | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 129 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
25 | 18 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BEVESPI AEROSPHERE open payments reported associated product |
CMS Open Payments — General Payments 763 supporting records · 473 recipient NPIs · example record 1206131384 |
Bevespi Aerosphere · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
94 | 35 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
114 | 36 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
129 | 34 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
49 | 17 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 608 | 223 |
| Amlodipine Besylate | Amlodipine Besylate | 435 | 150 |
| Metoprolol Succinate | Metoprolol Succinate | 332 | 122 |
| Losartan Potassium | Losartan Potassium | 295 | 113 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 264 | 104 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 241 | 93 |
| Metformin Hcl | Metformin Hcl | 241 | 83 |
| Levothyroxine Sodium | Levothyroxine Sodium | 239 | 87 |
| Eliquis | Apixaban | 228 | 49 |
| Ezetimibe | Ezetimibe | 206 | 85 |
| Gabapentin | Gabapentin | 201 | 82 |
| Fluticasone Propionate | Fluticasone Propionate | 194 | 75 |
| Tamsulosin Hcl | Tamsulosin Hcl | 162 | 68 |
| Pravastatin Sodium | Pravastatin Sodium | 150 | 49 |
| Montelukast Sodium | Montelukast Sodium | 147 | 64 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 129 | 34 |
| Omeprazole | Omeprazole | 128 | 58 |
| Pantoprazole Sodium | Pantoprazole Sodium | 121 | 49 |
| Jardiance | Empagliflozin | 114 | 36 |
| Allopurinol | Allopurinol | 112 | 45 |
| Lisinopril | Lisinopril | 111 | 41 |
| Hydrochlorothiazide | Hydrochlorothiazide | 107 | 43 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 100 | 40 |
| Famotidine | Famotidine | 98 | 44 |
| Farxiga | Dapagliflozin Propanediol | 94 | 35 |
| Furosemide | Furosemide | 91 | 37 |
| Mounjaro | Tirzepatide | 88 | 16 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 88 | 28 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 87 | 23 |
| Methylprednisolone | Methylprednisolone | 86 | 65 |
| Amoxicillin | Amoxicillin | 85 | 67 |
| Azithromycin | Azithromycin | 79 | 62 |
| Quetiapine Fumarate | Quetiapine Fumarate | 78 | 26 |
| Carvedilol | Carvedilol | 74 | 26 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 74 | 28 |
| Diclofenac Sodium | Diclofenac Sodium | 71 | 28 |
| Repaglinide | Repaglinide | 71 | 20 |
| Valsartan | Valsartan | 69 | 26 |
| Fenofibrate | Fenofibrate Nanocrystallized | 68 | 28 |
| Enalapril Maleate | Enalapril Maleate | 67 | 25 |
| Ozempic | Semaglutide | 66 | 20 |
| Alendronate Sodium | Alendronate Sodium | 65 | 27 |
| Ibuprofen | Ibuprofen | 65 | 25 |
| Linzess | Linaclotide | 64 | 17 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 63 | 21 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 63 | 29 |
| Clopidogrel | Clopidogrel Bisulfate | 61 | 27 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 60 | 51 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 58 | 18 |
| Doxepin Hcl | Doxepin Hcl | 54 | 23 |
| Alprazolam | Alprazolam | 50 | suppressed |
| Simvastatin | Simvastatin | 50 | 17 |
| Entresto | Sacubitril/Valsartan | 49 | 17 |
| Finasteride | Finasteride | 48 | 26 |
| Azelastine Hcl | Azelastine Hcl | 47 | 23 |
| Symbicort | Budesonide/Formoterol Fumarate | 47 | suppressed |
| Xarelto | Rivaroxaban | 47 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 45 | 14 |
| Ketoconazole | Ketoconazole | 43 | 24 |
| Tradjenta | Linagliptin | 43 | 15 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 39 | 13 |
| Celecoxib | Celecoxib | 38 | 13 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 38 | 13 |
| Santyl | Collagenase Clostridium Hist. | 37 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 36 | 13 |
| Vascepa | Icosapent Ethyl | 36 | 12 |
| Folic Acid | Folic Acid | 35 | 14 |
| Januvia | Sitagliptin Phosphate | 35 | 12 |
| Creon | Lipase/Protease/Amylase | 34 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 34 | 11 |
| Glimepiride | Glimepiride | 34 | 14 |
| Nifedipine Er | Nifedipine | 34 | 14 |
| Naproxen | Naproxen | 33 | 17 |
| Nebivolol Hcl | Nebivolol Hcl | 33 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 32 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 31 | 17 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 31 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 30 | 16 |
| Nitroglycerin | Nitroglycerin | 29 | 19 |
| Glipizide | Glipizide | 28 | 11 |
| Memantine Hcl | Memantine Hcl | 28 | 15 |
| Restasis | Cyclosporine | 28 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 27 | suppressed |
| Meloxicam | Meloxicam | 27 | 17 |
| Prednisone | Prednisone | 27 | 19 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 26 | 18 |
| Chlorthalidone | Chlorthalidone | 26 | 11 |
| Single Use Swab | Alcohol Antiseptic Pads | 26 | 17 |
| Zenpep | Lipase/Protease/Amylase | 26 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 25 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 25 | 12 |
| Prolia | Denosumab | 25 | 18 |
| Ramipril | Ramipril | 25 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 24 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 24 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 23 | suppressed |
| Synthroid | Levothyroxine Sodium | 23 | suppressed |
| Spironolactone | Spironolactone | 22 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 21 | suppressed |
| Fluconazole | Fluconazole | 21 | 12 |
| Valacyclovir | Valacyclovir Hcl | 21 | 15 |
| Atenolol | Atenolol | 20 | suppressed |
| Hydrocortisone | Hydrocortisone | 20 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 20 | suppressed |
| Myrbetriq | Mirabegron | 20 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 19 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 19 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Levetiracetam | Levetiracetam | 17 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 16 | suppressed |
| Methotrexate | Methotrexate Sodium | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 16 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 15 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 15 | 11 |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 15 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 14 | 12 |
| Mitigare | Colchicine | 14 | suppressed |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 14 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 14 | suppressed |
| Restasis Multidose | Cyclosporine | 14 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 13 | 12 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 13 | suppressed |
| Bevespi Aerosphere | Glycopyrrolate/Formoterol Fum | 13 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 13 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 13 | suppressed |
| Jublia | Efinaconazole | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 13 | suppressed |
| Baclofen | Baclofen | 12 | suppressed |
| Enalapril-Hydrochlorothiazide | Enalapril/Hydrochlorothiazide | 12 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Lidocaine | Lidocaine | 12 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 12 | suppressed |
| Rybelsus | Semaglutide | 12 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 12 | suppressed |
| Trulicity | Dulaglutide | 12 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 12 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 11 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 11 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 11 | suppressed |
| Torsemide | Torsemide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $472.15 · 22 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AMVUTTRA, BREZTRI, ENTRESTO, FARXIGA, JARDIANCE, LEQVIO, LOKELMA, Ohtuvayre, Repatha, TRELEGY ELLIPTA, YUPELRI, Zypitamag | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Entresto play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error